Kornimate/medical-research-clean huggingface dataset:
workstation pilot study

Conditions: Obesity; Sedentary Lifestyle

Summary: this is a pilot study to assess the feasibility of using treadmill desks (workstations) within a louisiana office workplace and to determine the effects of walking while working in overweight or obese, sedentary individuals.

eligible participants will be randomized by chance to the workstation intervention group or to a usual working condition group. the workstation intervention group will be asked to walk for up to 1.5 hours per day during the work week of monday through friday on the treadmill. participants will complete two sessions per day for up to 45 minutes per session, tracking time and speed. usual working condition group will be asked to continue working in usual environment and accustomed manner. regardless of which group the participants are assigned to, the participants will be asked to complete baseline and follow up assessment visits. months 3 and 6 for approximately 1 hour for body measurements (height, weight and waist circumference), body fat percent, gait speed, questionnaires, and accelerometry.

Eligibility criteria:
inclusion criteria: * males or females * bmi ≥ 25 kg/m2 * willing to give informed consent * willing to accept randomization to group assignment and willing to follow the protocol for the group to which they have been assigned * willing to maintain fulltime employment at the company for the next 6 months * willing to receive frequent contacts and communication from study staff over the next 6 months exclusion criteria: * current participation in other pennington biomedical research studies * bmi \< 25 kg/m2 * type 1 diabetes * average step count of ≥ 7,500 steps/day * self-reporting exercising \> 20 minutes on 3 or more days/wk, within the past 6 months * unable to walk 45 minutes continuously without taking a rest * unable to walk without the use of an assistive device, such as a cane or walker * have had a cardiovascular event (stroke or heart attack) in the past 6 months * have a pacemaker or any other internal electrical medical device * have been diagnosed with schizophrenia or bipolar disorder * have any condition that would limit participation in a physical activity program * women who are pregnant, have been pregnant in the last 6 months, or are breastfeeding * actively participating in a weight loss program * plan to move out of the study area within the next 6 months or plan to be away from work for more than 4 weeks in the next 6 months * have another member of household participating in the study * have any condition, which, in the opinion of the investigator would impede competence or compliance or possibly hinder completion of the study

Keywords: walking physical activity sedentary behavior workplace
hypofractionated stereotactic radiotherapy with anlotinib in patients with recurrent high-grade gliomas

Conditions: Malignant Glioma

Summary: a phase ii study of hypofractionated stereotactic radiotherapy (hsrt) with anlotinib in patients with recurrent high-grade glioma. the primary endpoint is overall survival after radiotherapy. secondary endpoints included progress-free survival, objective response rate, cognitive function, quality of life, toxicity.

original histopathologically proven diagnosis world health organization (who) grade 3/4 glioma patients who underwent surgery, chemoradiotherapy and adjuvant chemotherapy (stupp protocol). recurrence based on response assessment in neuro-oncology (rano) criteria and/or histopathology. intervention included cyberknife hypofractionated stereotactic radiotherapy (25gy/5fx) with anlotinib once daily (12mg/d) on days 1-14 of a 21-day cycle.

Eligibility criteria:
inclusion criteria: 1. 18-70 years of age; 2. karnofsky performance status (kps) ≥ 60; 3. original histopathologically proven diagnosis world health organization (who) grade 4 glioma; 4. underwent surgery, chemoradiotherapy and adjuvant chemotherapy (stupp protocol) after initial diagnosis, recurrent based on the response assessment in neuro-oncology (rano) criteria and/or histopathologically proven; 5. measurable disease; 6. estimated survival of at least 3 months; 7. hgb \> 9 gm; absolute neutrophil count (anc) \> 1500/μl; platelets \> 100,000; creatinine \< 1.5 times the upper limit of laboratory normal value; bilirubin \< 2 times the upper limit of laboratory normal value; serum glutamate pyruvate transaminase (sgpt) or serum glutamate oxaloacetate transaminase (sgot) \< 3 times the upper limit of laboratory normal value; 8. signed informed consent form; 9. agreed to participate the follow-up. exclusion criteria: 1. prior invasive malignancy unless disease free; 2. received re-irradiation; 3. more than 3 relapses or evidence of subtentorial recurrent disease or tumor greater than 6 cm in maximum diameter; 4. prior therapy with an inhibitor of vascular endothelial growth factor (vegf) or vegfr; 5. pregnancy or or nursing mothers; 6. participated in other trials after diagnosis of recurrent; 7. influence factors toward oral medications; 8. patients with ctcae5.0 grade 3+ bleeding; 9. suffering from severe cardiovascular disease: myocardial ischemia or myocardial infarction above grade ii, poorly controlled arrhythmias (including men with qtc interval ≥ 450 ms, women ≥ 470 ms); according to nyha criteria, grades iii to iv insufficient function, or cardiac color doppler ultrasound examination indicates left ventricular ejection fraction (lvef) \<50%; 10. long-term unhealed wounds or fractures; 11. history of organ transplantation; 12. serious diseases that endanger patients' safety or affect patients' completion of research,according to the researchers' judgment.

Keywords: hypofractionated stereotactic radiotherapy recurrent high-grade glioma anlotinib
macular pigment optical density in primary angle-closure disease

Conditions: Glaucoma; Glaucoma, Angle-Closure; Macular Pigment Optical Density

Summary: glaucoma is the leading cause of irreversible blindness in the world, and primary angle-closure glaucoma (pacg) is the most important type of glaucoma in asia. primary angle closure disease (pacd) is a group of diseases related to pacg, and the pathogenesis is still unclear. macular pigment has the functions of filtering short-wavelength waves and anti-oxidation, which are related to visual function. previous studies have found that the macular pigment density (mpod) is significantly reduced in primary open-angle glaucoma. this project uses the single-wavelength reflection method to measure mpod, observes the characteristics of pacd and the normal control group's changes in retinal mpod, and explains the relationship between pacd's mpod changes and angle-closure glaucoma optic nerve damage

observation index： visual acuity，intraocular pressure，ophthalmoscope，mpod，visual field and oct. inspection parameters of oct： 1. retinal nerve fiber layer thickness 2. ganglion cell complex thickness 3. mean thickness of the central retina 4. mean defect

Eligibility criteria:
inclusion criteria: * experimental group： * (1) according to the diagnostic criteria of pacd * (2)history of peripheral iridectomy or trabeculectomy * (3)over 40 * (4)phakic eyes * (5)intraocular pressure is less than 21mmhg, more than one week * (6)eyes with clear optical media. * control group： * (1)no history of glaucoma and other eye diseases * (2)phakic eyes * (3)over 40 * (4)intraocular pressure10\~21mmhg exclusion criteria: * (1)history of corneal diseases * (2)history of eye tumor or other ophthalmic surgery * (3)cataract * (4)taking supplements containing lutein within 6 months * (5)snellen's visual acuity was less than 6 / 20，the diopter is beyond ± 6 degrees

Keywords: glaucoma, angle-closure pacd-primary angle closure disease macular pigment optical density
diagnosis of cow's milk protein allergy

Conditions: Cow's Milk Allergy

Summary: the study will assess the diagnosis of cow's milk protein allergy (cmpa) among infant and children in assiut university children hospital using skin prick test and specific serum ige as well as their management.

food allergy is a reproducible specific immune response to exposure to a given food. cow's milk protein allergy (cmpa) is clinically abnormal reaction to cow's milk protein (cmp) via immune mechanisms triggered by milk protein (boyce etal.,2010). according to european academy for allergy and clinical immunology (eaaci) and the world allergy organization (wao) , a hypersensitivity reaction to cow's milk involving the immune system can be called as cmpa. there is difference between cmpa and non-allergic cow's milk intolerance (e.g lactose intolerance) which occurs as a result of lactase deficiency without involvement of the immune system (venter etal.,2013). cmpa is categorized into immunoglobulin ige mediated , non -ige mediated ,or mixed cmpa (sicherer etal.,2001). 1.9% to 4.9% prevalence of cmpa among children with a peak in prevalence (2-3%) in the first year of life and prevalence of \ =6 years (koletzko etal.,2012).

Eligibility criteria:
inclusion criteria: * - exclusively breast feeding ,breast-fed infants with supplementary foods and non-breast fed infants with supplementary foods who complain from either frequent regurgitation, vomiting,diarrhea,constipation (with/without perianal rash) ,blood in stool or pallor. exclusion criteria: * : infant and child with gastrointestinal symptoms due to specific etiology.
a study to evaluate the safety and efficacy of ruxolitinib phosphate cream applied topically to adults with atopic dermatitis

Conditions: Atopic Dermatitis

Summary: the purpose of this study is to establish the efficacy of each strength of ruxolitinib cream once daily (qd) or twice daily (bid) in participants with atopic dermatitis as compared with vehicle cream bid.


Eligibility criteria:
inclusion criteria: * participants diagnosed with atopic dermatitis (ad) as defined by the hanifin and rajka criteria. * participants with a history of ad for at least 2 years. * participants with an investigator's global assessment (iga) score of 2 to 3 at screening and baseline. * participants with body surface area (bsa) of ad involvement, excluding the face and intertriginous areas, of 3% to 20% at screening and baseline. * participants who agree to discontinue all agents used to treat ad from screening through the final follow-up visit. exclusion criteria: * participants with evidence of active acute or chronic infections. * use of topical treatments for ad (other than bland emollients) within 2 weeks of baseline. * systemic immunosuppressive or immunomodulating drugs (eg, oral or injectable corticosteroids, methotrexate, cyclosporine, mycophenolate mofetil, azathioprine) within 4 weeks or 5 half-lives of baseline (whichever is longer). * participants with other dermatologic disease besides ad whose presence or treatments could complicate the assessment of disease (eg, psoriasis). * participants with a history of other diseases besides dermatologic disorders (eg, other autoimmune diseases) taking treatments that could complicate assessments. * participants with cytopenias at screening, defined as: * leukocytes \< 3.0 × 10\^9/l. * neutrophils \< lower limit of normal. * hemoglobin \< 10 g/dl. * lymphocytes \< 0.8 × 10\^9/l * platelets \< 100 × 10\^9/l. * participants with severely impaired liver function (child-pugh class c) or end-stage renal disease (esrd) on dialysis or at least 1 of the following: * serum creatinine \> 1.5 mg/dl. * alanine aminotransferase (alt) or aspartate aminotransferase (ast) ≥ 1.5 × upper limit of normal. * participants taking potent systemic cytochrome p450 3a4 inhibitors or fluconazole within 2 weeks or 5 half-lives, whichever is longer, before the baseline visit (topical agents with limited systemic availability are permitted). * participants who have previously received janus kinase (jak) inhibitors, systemic or topical (e.g., ruxolitinib, tofacitinib, baricitinib, filgotinib, lestaurtinib, pacritinib).

Keywords: atopic dermatitis eczema pruritus janus kinase (jak) inhibitors
pain control after lumbar spine fusion

Conditions: Spine Fusion; NSAID (Non-Steroidal Anti-Inflammatory Drug); Postoperative Pain

Summary: the purpose of this randomized controlled trial is to determine if patients who receive non-steroidal anti-inflammatory medications (nsaids) following elective lumbar spinal fusion have increased rates of symptomatic nonunion requiring revision spinal surgery at two-years follow-up, compared to those who do not receive nsaids.


Eligibility criteria:
inclusion criteria: * ≥18 years of age, ≥1-level planned lumbar spinal fusion * capacity to enroll * english speaking exclusion criteria: * chronic kidney disease (preoperative creatinine ≥1.4) * history of gastrointestinal bleed or peptic ulcer disease * history of spinal fusion nonunion * non-steroidal anti-inflammatory drug allergy * previously diagnosed coagulopathy * preoperative thrombocytopenia (platelets \<100,000) * connective tissue disease * operative indication due to infection, neoplasm, or trauma * currently pregnant
eus-fna versus khb in diagnostics of upper gastrointestinal submucosal tumors

Conditions: Other Specified Disorders of Esophagus, Stomach or Duodenum

Summary: upper gastrointestinal submucosal tumors are tumors arising from subepithelial layers of esophageal, gastric or duodenal wall. they usually have an intact mucosa lining on the inner surface. the prognosis and treatment of these tumors depend on their correct diagnostics and mitotic activity in case of gastrointestinal stromal tumors (gist). a standard forceps biopsy of mucosa is usually not helpful. therefore, biopsy techniques capable of reaching deeper layer of upper gut are needed. the investigators compare khb and eus-fna in the diagnostics of upper gastrointestinal submucosal tumors.

patients with endoscopically detected submucosal tumors of upper gut with diameter ≥ 2cm are enrolled in the trial. according to randomization, the patients are allocated to either eus-fna by 22g needle or khb consisting of forceps biopsy through mucosal incision by a needle knife, both with subsequent histological/cytological and immunohistochemical evaluation of the specimen. the success of tissue diagnostics was evaluated as well as the possibility to determine the mitotic activity in case of gist. in case of failure of the initial method, the other method was performed (cross-over design). patients are hospitalized and kept under observation during 24 hours after the biopsy.

Eligibility criteria:
inclusion criteria: * submucosal tumor with endoscopically normal intact mucosa * tumor size: 20mm or more * localization of tumors: esophagus,stomach, duodenum * age: 18 years and older * the patient´s consent with a diagnostic procedure . exclusion criteria: * endoscopically nonbuilding tumor * patients younger than 18 years * coagulopathy (inr \> 1,5, platelets \< 100) * tumor size \< 20mm

Keywords: key hole biopsy upper gastrointestinal submucosal tumors eus-fna mitototic activity gist
escin in patients with covid-19 infection

Conditions: Coronavirus Infections

Summary: in december 2019,a new type of pneumonia caused by the coronavirus (covid-2019) broke out in wuhan ,china, and spreads quickly to other chinese cities and 28 countries. more than 70000 people were infected and over 2000 people died all over the world. there is no specific drug treatment for this disease. considering that lung damage is related to both viral infection and burst of cytokines, our idea is to evaluate the efficacy and safety of escin as add-on treatment to conventional antiviral drugs in covid-19 infected patients.


Eligibility criteria:
inclusion criteria: * aged between 18 and 75 years, extremes included, male or female * positivity to covid-19 screening test in molecular biology * in escin group: low response to standard treatment * ability to understand and the willingness to sign a written informed consent document exclusion criteria: * female subjects who are pregnant or breastfeeding. * patients with previous history to allergy * patients meet the contraindications of escin * patients have any condition that in the judgement of the investigators would make the subject inappropriate for entry into this study. * patients can't take drugs orally
knee osteoarthritis risk in retired professional footballers

Conditions: Osteoarthritis of the Knee

Summary: the oa and football study is an epidemiological study designed to establish the prevalence of knee osteoarthritis in retired professional footballers. the study will also identify the key risk factors associated with knee osteoarthritis. the study is comprised of three phases: phase i involves the dissemination of a questionnaire (demographic details, players history, injury and surgery and other known risk factors of oa), phase ii is a radiographic study that involves x-rays in a sample of footballers both with and without knee pain and phase iii is a case control study which will compared retired professional footballers with age-matched controls recruited from the general population in the east midlands region.

number of participants: phase i: 1000 phase ii: 855 phase iii: 500 primary outcome: the questionnaire will contain player specific information and will include validated outcome measures such as the health status questionnaire as well as self-reported pain, recall of injury and surgery history. the results of the questionnaire will be exported firstly to excel and subsequently, into ms access as part of a managed database.

Eligibility criteria:
phase i inclusion criteria: • all current or retired professional male footballers (registered with the professional footballer association (age range 40 -80) phase ii inclusion criteria: * professional footballers both with and without a history of knee pain knee oa or knee surgical history * no contraindications of the affected joint such as gout or rheumatoid arthritis * willingness to participate in a clinical assessment of the knee and provision of blood samples. phase iii inclusion criteria for controls: * over the age of 40 (age range 40 - 80) * both with and without a history of knee pain over at least the last 1 year * no history of significant trauma, injury or surgery to the lower limb * american college of rheumatology (acr) classification of oa based on physical examination and clinical presentation: pain in the knee and three of the following; over the age of 50, less than 30 minutes of morning stiffness, crepitus on active motion, bony tenderness, bony enlargement and no palpable warmth of synovium. phase i exclusion criteria: * not a registered professional footballer (current or past) * inaccurate information (discrepancy with questionnaire information compared to other football records. this will be verified by the co-investigator, dr fernandes and mr sanjay parekh) * incomplete questionnaire or duplicate questionnaire. phase ii exclusion criteria: * not a registered professional footballer * no written informed consent to participate phase iii exclusion criteria: * aged 39 and under * comorbidities such as rheumatoid arthritis, gout, osteoporosis * history of injury, trauma or surgery to the lower limb.

Keywords: knee osteoarthritis epidemiology risk factors prevalence professional football
usefulness of 3d digital reconstruction in the imaging diagnosis of pancreatic tumors

Conditions: Pancreas Neoplasm

Summary: reconstruction using 3d virtual models has brought about a revolution in diagnostic imaging and its use is increasingly widespread. the objective of this work is to determine the precision of the 3d model when establishing the characteristics of tumors and their relationship with other anatomical structures.


Eligibility criteria:
inclusion criteria: * patients with suspected pancreatic tumor.

Keywords: 3d virtual model
an observational study of bevacizumab in chinese patients with metastatic colorectal cancer

Conditions: Metastatic Colorectal Cancer

Summary: this observational, multicenter, prospective study will evaluate the use of bevacizumab in real clinical practice in chinese patients with metastatic colorectal cancer.


Eligibility criteria:
inclusion criteria: * histologically confirmed metastatic colorectal cancer patients having initiated treatment with bevacizumab exclusion criteria: * non-metastatic colorectal cancer patients not recieved bevacizumab

Keywords: bevacizumab overall survival adverse events tumor resection rate
autonomic small fiber neuropathy and ehlers danlos syndromes - prospective study and registry

Conditions: Autonomic Neuropathy; Ehlers-Danlos Syndrome Hypermobility Type; Small Fiber Neuropathy; Postural Tachycardia Syndrome

Summary: we examine patients with different autonomic neuropathies and ehlers danlos syndromes compared to healthy controls at three different points over time (baseline, after 3 months and after 1.5 years) to gain knowledge about the course of this disease and understand its pathophysiology, with a focus on small fiber neuropathy. moreover we will validate the german version of the malmö pots score and establish an easy diagnostic scheme for patients in outpatient care.

inclusion of patients with autoimmune autonomic neuropathies/ pure autonomic failure, postural orthostatic tachycardia syndrome, small fiber neuropathies, ehlers-danlos syndromes, mast cell activation syndrom, chronic fatigue syndrome and postcovid syndrome in our registry study with follow up visits. comparison to healthy controls concerning selected examinations. planned examinations are laboratory tests, questionnaires on mental and physical health status and circulatory disorders, attention tests, tilt table testing, standing test, sweat function, investigation of small fiber function via quantitative sensory testing as well as the density of nerve fibers in the skin. measurements are performed at baseline mostly in clinical routine and follow up visits are offered.

Eligibility criteria:
inclusion criteria: * autonomic neuropathy * postural orthostatic tachycardia syndrome * hypermobile or classical ehlers danlos syndromes * chronic fatigue syndrome, mast cell activation syndrome and/or postcovid * healty controls * between 18-80 years * in patients: diagnosis and clinical testing in our outpatient clinic * german speaking exclusion criteria: * pregnancy * pacemaker or deep brain stimulation * sensory or motor polyneuropathy * neurodegenerative disease